Sustained Minimal Residual Disease (MRD) Negativity for ≥1 Year in Transplant Eligible Newly Diagnosed Multiple Myeloma (NDMM): A Systematic Review of Prospective Clinical Trials | Synapse
March 3, 2026
Sustained Minimal Residual Disease (MRD) Negativity for ≥1 Year in Transplant Eligible Newly Diagnosed Multiple Myeloma (NDMM): A Systematic Review of Prospective Clinical Trials
Key Points
Sustained minimal residual disease (MRD) negativity for one year supports better prognosis in multiple myeloma patients.
The systematic review encompasses diverse prospective clinical trials assessing various treatment regimens.
A focus on transplant-eligible patients highlights the importance of early intervention for optimal outcomes.
Future studies should explore long-term effectiveness and the applicability of these findings to broader patient populations.